Eli Lilly and Company (NYSE:LLY) Shares Sold by Regal Investment Advisors LLC

Regal Investment Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 29.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,238 shares of the company's stock after selling 1,350 shares during the period. Regal Investment Advisors LLC's holdings in Eli Lilly and Company were worth $2,500,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after purchasing an additional 60,306 shares during the period. M&T Bank Corp increased its holdings in Eli Lilly and Company by 0.7% in the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after buying an additional 1,867 shares in the last quarter. Invst LLC lifted its position in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after acquiring an additional 189 shares during the period. McIlrath & Eck LLC boosted its stake in shares of Eli Lilly and Company by 3.4% during the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock worth $426,000 after acquiring an additional 16 shares in the last quarter. Finally, Virtu Financial LLC grew its holdings in shares of Eli Lilly and Company by 111.7% in the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock worth $5,786,000 after acquiring an additional 3,446 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Up 14.5 %

LLY traded up $106.80 on Friday, reaching $841.70. 10,843,294 shares of the company's stock were exchanged, compared to its average volume of 3,427,404. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company's 50 day moving average is $829.09 and its 200-day moving average is $819.40. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market cap of $798.08 billion, a price-to-earnings ratio of 71.88, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Truist Financial boosted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Morgan Stanley decreased their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Guggenheim lowered their price target on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Finally, Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Two research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,012.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.